Litcius/Paper detail

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

Fredrik Schjesvold, Paul G. Richardson, Thierry Façon, Adrían Alegre, Andrew Spencer, Artur Jurczyszyn, Kazutaka Sunami, Laurent Frenzel, Chang‐Ki Min, Sophie Guillonneau, Peggy L. Lin, Solenn Le-Guennec, Frank Campana, Helgi van de Velde, Samira Bensfia, Sara Bringhen

2020Haematologica30 citationsDOIOpen Access PDF

Abstract

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed

Topics & Concepts

PomalidomideDexamethasoneMultiple myelomaInternal medicineSubgroup analysisMedicineOncologyRefractory (planetary science)LenalidomideBiologyMeta-analysisAstrobiologyMultiple Myeloma Research and TreatmentsPeptidase Inhibition and AnalysisProtein Degradation and Inhibitors
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis | Litcius